🇪🇺 Nevirapine (NVP) in European Union

EMA authorised Nevirapine (NVP) on 4 February 1998

Marketing authorisation

EMA — authorised 4 February 1998

  • Application: EMEA/H/C/000183
  • Marketing authorisation holder: Boehringer Ingelheim International GmbH
  • Local brand name: Viramune
  • Indication: Viramune 50 mg/5 mL oral suspension and 200 mg tablets Viramune is indicated in combination with other anti-retroviral medicinal products for the treatment of HIV-1 infected adults, adolescents, and children of any age.Most of the experience with Viramune is in combination with nucleoside reverse transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune should be based on clinical experience and resistance testing. Viramune 400 mg prolonged-release tablets Viramune is indicated in combination with other anti-retroviral medicinal products for the treatment of HIV-1 inf
  • Status: approved

Read official source →

Other Infectious Disease / Virology approved in European Union

Frequently asked questions

Is Nevirapine (NVP) approved in European Union?

Yes. EMA authorised it on 4 February 1998.

Who is the marketing authorisation holder for Nevirapine (NVP) in European Union?

Boehringer Ingelheim International GmbH holds the EU marketing authorisation.